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 Blood pressure is an important risk factor for cardiovascular disease (CVD). 
 Soy intake has a favorable effect on blood pressure. 
 Subgroup analysis showed a reduction in systolic and diastolic blood pressure in younger 














Background: Soy has several beneficial effects on cardiovascular disease (CVD); however, 
results of clinical trial studies are equivocal. Thus, the present study sought to discern the efficacy 
of soy intake on blood pressure. 
Methods: The search process was conducted in PubMed, Scopus, Web of Science, and Cochrane 
Library, to ascertain studies investigating the efficacy of soy intake on blood pressure in adults, 
published up to June 2020. A random-effects model was applied to pool mean difference and 95% 
confidence intervals (CIs). Meta-regression analysis was performed to discern potential sources of 
heterogeneity. Begg’s and Egger’s methods were conducted to assess publication bias.  
Results: Pooled effects from 17 studies revealed a significant improvement in systolic blood 
pressure (SBP) (-1.64; -3.25 to -0.04 mmHg; I2 = 50.5 %) and diastolic blood pressure (DBP) (-
1.21; -2.29 to -0.12 mmHg, I2 = 50.7 %) following soy consumption, in comparison with controls. 
Subgroup analysis demonstrated a reduction in both SBP and DBP in younger participants with 
lower baseline blood pressure and intervention durations of <16 weeks. 
Conclusion: Our results suggest that soy intake is associated with an ameliorating effect on blood 
pressure in adults. 
Keywords: Soy, Blood pressure, Hypertension, Review, Meta-analysis 
 
Introduction: 
Soy is a traditional food that is globally popular, especially in Asia, and is widely used to produce 
various food products, such as soybean oil, soy milk, soy flour, and many retail food products [1]. 











economic effects by reducing production costs and standardizing quality [2, 3]. Soybean contains 
compounds such as protein, fiber, vitamins, minerals, and phytochemicals, which has led to 
considerable research interest regarding its effects on various diseases [1, 4]. Accordingly, 
previous studies have reported protective features of soy in diabetes, cancer, osteoporosis, and 
menopausal problems [3], with further studies confirming its beneficial effects on cardiovascular 
disease (CVD) [5]. 
One of the most important risk factors of CVD is hypertension, which represents one of the most 
prevalent non-communicable diseases, worldwide [6]. Several strategies, including medication 
and lifestyle modification are recommended to manage the disorder [7], whilst numerous studies 
have been performed to investigate the effects of nutrients on blood pressure [8]. For instance, the 
Dietary Approaches to Stop Hypertension (DASH) diet has been advocated as part of the treatment 
protocol for hypertensive patients [9]. Moreover, there are several studies demonstrating the 
effectiveness of macronutrients on blood pressure [10, 11]. In the case of total protein intake, 
however, the results manifest in the literature are contradictory, although the positive effect of 
plant based protein on blood pressure has been confirmed [12]. In addition, although observational 
studies [13, 14] have confirmed the efficacy of soy as a vegetable protein on blood pressure, the 
results of clinical trial studies are equivocal [15, 16]. 
Due to the limited number of participants in previous clinical trial studies [17, 18], as well as 
differences in intervention duration [19, 20], age [21, 22], and baseline blood pressure [18, 21, 23], 
it is not possible to draw any firm conclusion regarding the effect of soy on blood pressure. 
Therefore, in this study we aimed to identify the effect of soy intake on blood pressure by 












We undertook our study in accordance with guidelines proposed by the Preferred Reporting Items 
for Systematic reviews and Meta-Analyses (PRISMA) [24]. The review protocol was registered 
with PROSPERO (CRD42020214728). 
Search process: 
To identify relevant papers investigating the effect of soy on blood pressure, we undertook a 
systematic search in PubMed, Embase, Scopus, Web of Science, and Cochrane Library, for all 
available publications up to June 2020, using a combination the relevant terms in titles and 
abstracts, without making any restrictions (Supplementary material 1). In some cases, we used 
the wildcard term “*” to increase sensitivity and checked the reference lists of the relevant reviews 
and Google Scholar to supplement the database search strategy, which was prepared with in-group 
consensus. After loading retrieved records into EndNote, duplicates were removed.  
Inclusion and exclusion criteria: 
Four authors independently assessed the records retrieved from the database search. Randomized 
controlled trials (RCTs) investigating the association of soy intake and blood pressure in adults (> 
18 years of age) were identified for inclusion. To maximize methodological rigor, only double-
blind placebo-controlled trials were then shortlisted for inclusion, to increase quality of evidence, 
and reduce potential bias in the meta-analysis. Review articles, dissertations, brief reports, 
observation-designed and non-English language studies were excluded, as were those lacking 
clinical information or statistical data required for analysis (e.g. baseline of blood pressure, 
standard deviation (SD), standard error (SE), 95 % confidence intervals (CI) and interquartile 











discussion. For example, one study did not clearly mention term “placebo” as the control [21], 
however, the study-design was comparable to a placebo-controlled design. Following discussion 
with clinical and statistical experts, this study was included. In addition, studies were excluded if 
the control group was not clinically comparable with the intervention, and therefore inclusion 
would have biased the results. Trials that prescribed effective nutrients, diet, drugs, or other 
combinations concomitant to soy, in comparison with controls were also excluded. 
Data extraction: 
After identifying studies for inclusion, a combination of four authors extracted clinical and 
statistical data, including: first authors last name, corresponding author’s e-mail, publication year, 
country, population, participants’ characteristics, intervention and control type, dose and type of 
supplement, treatment duration, sample size, methodological quality, mean change of interested 
outcome from baseline at the end of trial, related SD, SE, 95% CI or IQR. Where required 
appropriate transformations were undertaken to calculate the SD from studies reporting: SE (SD 
= SE × √n), 95 % CI (SD = √n × (upper limit − lower limit) ∕ 3.92) or IQR (SD = IQR / 1.35) [25]. 
In addition, WebPlotDigitizer (https://automeris.io/WebPlotDigitizer) was used to derive the mean 
change and the corresponding SD when the data were plotted, but not reported. 
Quality appraisal: 
Two authors independently assessed quality in the included studies using the Cochrane 
Collaboration risk of bias assessment tool [26], which is scored across seven domains being: 
random sequence generation (selection bias), allocation concealment (selection bias), blinding of 
participants and personnel (performance bias), blinding of outcome assessment (detection bias), 











bias. Each included study also received an overall grading of Good (> 2 low risk domains), Fair 
(= 2 low risk domains), or Poor (< 2 low risk domains). 
Statistical analysis: 
Weighted mean difference (WMD) and 95% CI was calculated in Stata v.13, applying a random-
effects method. Inter-study heterogeneity was evaluated by checking I2 index [27]. Given the 
existence of moderate to high heterogeneity, a meta-regression by age, intervention duration, and 
baseline blood pressure was planned to identify potential sources. In addition, subgroup analyses 
were planned by effective clinical covariates i.e. age (> 56, < 56 years old), baseline blood pressure 
(SBP: > 130, < 130 mmHg; DBP: > 80, < 80 mmHg), intervention duration (< 16, > 16 weeks) 
and region (Asia, Europe, America). 
Mean changes and their SDs of relevant outcomes were obtained by using the following equations: 
[mean-post – mean-baseline] and [(√ ([(SD pre)2 + (SD post)2] – [2r × SD pre × SD post]))] [28], 
respectively. Correlation coefficients (r) were calculated for each outcome of interest, using an 
appropriate formula, as proposed in the Cochrane guidelines for systematic reviews and meta-
analysis [27], and was estimated as 0.5. In addition, a sensitivity analysis was applied by discarding 
each trial in turn, to ensure robustness of results. A Begg's rank-correlation [29] and Egger’s 
regression asymmetry [30] were performed to evaluate potential publication bias.  P-values of less 
than 0.05 represented statistical significance.  
Results: 











From 3,163 records, 15 RCTs with 17 effect sizes were identified for inclusion, all of which were 
able to be included in the meta-analysis (Figure 1). These studies were published between 2001 
and 2015. Ten were conducted in Asia [17, 19, 20, 21, 22, 31, 32, 33, 34, 35], four in Europe [18, 
23, 36, 37], and another one in the United States of America [38]. Participant age ranged from 
50.32 to 66.8 years. Intervention durations were less than 16 weeks [17, 18, 20, 21, 22, 23, 31, 32, 
33] or more than 16 weeks [19, 34, 35, 36, 37, 38] in nine and six trials, respectively.  
Baseline blood pressure across studies was reported as SBP < 130 mmHg [17, 20, 33, 34, 35, 38] 
and > 130 mmHg [18, 19, 21, 22, 23, 31, 32, 36, 37] in six and nine RCTs, respectively. In addition, 
enrolled participants of seven and eight studies had > 80mmHg [18, 19, 20, 21, 23, 32, 36] and < 
80mmHg [17, 22, 31, 33, 34, 35, 37] DBP, respectively.  
Quality assessment for included studies: 
Results of the quality assessment are shown in Table 2. Overall, study quality was assessed as 
good, with a low risk of bias the dominant classification across all domains. All studies were 
assessed as having low risk of bias for sequence generation and blinding of participants. Six studies 
were assessed as having unclear risk of bias for allocation concealment, five had unclear risk for 
blinding of outcome assessment, one had unclear risk for selective reporting and three had unclear 
risk for other potential sources of bias. Two studies were assessed as having high risk of bias for 
incomplete outcome data, with three assessed as unclear and the remaining 10 studies as low risk. 
Meta-analysis of blood pressure outcomes: 
A significant reduction in both SBP (WMD = -1.64 mmHg, 95 % CI = [-3.25, -0.04], P = 0.04, I2 
= 50.5 %) and DBP (WMD = -1.21 mmHg, 95 % CI = [-2.29, -0.12], P = 0.02, I2 = 50.7 %) were 











Subgroup analyses, identified a greater reduction in blood pressure for participants aged younger 
than 56 years (Figure 3, A and Figure 4, A), and those with lower baseline systolic (Figure 3, B) 
and diastolic (Figure 4, B) blood pressure. In addition, both systolic (Figure 3, C) and diastolic 
(Figure 4, C) blood pressure were significantly reduced when soy intake duration was < 16 weeks. 
Region-based subgroup analysis did not identify any significant change of blood pressure (Figure 
3, D and Figure 3, D). 
Meta-regression: 
Meta-regression was performed to assess the impact of potential covariates i.e. age, intervention 
duration, and baseline blood pressure on changes of SBP and DBP in response to soy intake. No 
significant association was found (Table 3). 
Publication bias and sensitivity analysis: 
Egger’s regression and Begg's rank-correlation tests indicated that there was no significant 
publication bias for SBP (P for Egger’s test = 0.97 and Begg’s test = 0.74) (Figure 5, A) or DBP 
(P for Egger’s test = 0.58 and Begg’s test = 0.45) (Figure 5, C). According to the findings from 
sensitivity analysis, pooled eff ect sizes obtained for the effect of soy intake on SBP (Figure 5, B) 




Data from 17 randomized double-blind placebo-controlled trials were available to examine 











significantly improves SBP and DBP. Subgroup analyses identified a greater reduction in blood 
pressure among younger participants with lower baseline blood pressure, and in trials lasting for 
< 16 weeks duration. 
The effect of soy consumption on blood pressure has been previously assessed in several RCTs. A 
study by Washburn et al indicated that 40 g of soy protein containing 68 mg of phytoestrogens, 
improved blood pressure abnormality [39]. In Teede et al., it was demonstrated that administration 
of 40 g of soy protein containing 118 mg of isoflavones, improved blood pressure in healthy men 
and women [31]. Furthermore, Welty et al. showed that a soy nut diet (containing 25 g of soy 
protein and 101 mg of aglycone isoflavones) lowered systolic blood pressure in hypertensive and 
normotensive patients [40]; whilst, Rivas et al. reported that a 3-month intervention with soymilk 
reduced blood pressure in men and women with mild-to-moderate hypertension, and that this 
hypotensive effect was related to urinary excretion of the isoflavonoid genistein [41]. Indeed, it 
has been shown that the BP-lowering effect of soy might be related to isoflavones [42], the 
suspected active ingredients in soy, via the activation of endothelial nitric oxide (NO) synthase 
(eNOS) and stimulation of NO production. Genistein is one of the soy isoflavones that can result 
in activation of eNOS and NO synthesis [43]. This is confirmed in another study where it was 
demonstrated that higher soy consumption is related to higher plasma concentrations of NO [44].  
It has been shown that oxidative stress and inflammation play a potential role in the development 
of hypertension [45]; thereby suggesting that soy isoflavones might lower BP through antioxidant 
and anti-inflammatory effects [46, 47]. In line with the meta-analysis by Liu et al [48], it is 
unsurprising that we did not observe an inverse relationship of soy consumption with BP among 
older people, largely due to the adverse structural changes in the vessel wall among this group [5]. 










consumption of phytoestrogens have been inversely related to arterial stiffness [5]. Moreover, soy 
consumption also reduces BP through its natriuretic effect, which is similar to furosemide [13].  
In the present study, we found that soy intake led to a higher reduction in blood pressure in 
participants with lower baseline systolic and diastolic BP, which is in contrast with result of the 
meta-analysis conducted by Liu et al. [48]. One reason that should be noted for this inconstancy is 
the difference in inclusion criteria regarding study design, inter-study heterogeneity, and risk of 
bias, which was lower across our pooled included studies. 
Strengths and limitations: 
The present meta-analysis is the first comprehensive study to have assessed the influence of soy 
intake on BP from randomized double-blind placebo-controlled trials. We used a comprehensive 
and accurate systematic search strategy, that allowed us to examine both indexed and non-indexed 
trials. To reduce between-study heterogeneity and potential bias, and also enhance the power of 
results, we only included studies in which the control group received a placebo and where a double-
blind design was employed. This approach improved quality of pooled analyses and subsequently 
permitting more rigorous insights in the effect of soy intake on BP. In addition, based on risk of 
bias assessment using Cochrane methodology, the quality of all studies was assessed overall as 
low risk. Subgroup analysis according to covariates that have clinical importance regarding soy 
intake and blood pressure improvements were pre-specified and provided additional insights to 
inform subsequent recommendations. It should be noted that there was no significant publication 
bias found, whilst pooled results were not sensitive to any individual study. However, despite the 
clear novelty of this work, our study has some limitations that should be noted. First, although we 
conducted meta-regression analysis, we were unable to discern the source of heterogeneity based 











only reported soy, we were not able to apply a dose-response analysis. Third, we could not conduct 
subgroup analysis or meta-regression for baseline BMI and body weight of participants, which 
could be clinically important markers related to the change of BP, because of their absence in some 
included trials. Moreover, due to a variety of diseases among included study participants and lack 
of essential clinical data about their metabolic markers, we were not able to conduct additional 
subgroup analysis based on type of diseases without reducing the power of the analysis. Finally, 
although we contacted some corresponding authors to request missing essential data, in most cases, 
we received no response, or unsatisfactory responses. 
Conclusion 
In the present study, pooled effect sizes from 17 studies revealed a significant improvement in 
SBP and DBP in adults following soy consumption, in comparison with controls. In addition, 
subgroup analysis indicated a further reduction in both SBP and DBP in younger participants with 
lower baseline blood pressure and intervention durations < 16 weeks. Thus, increases to soy 
consumption could be considered as an alternative or complementary approach to improving BP 
outcomes among adults, and particularly among younger adults.  
Author contribution: 
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria 
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 Figure 1. The process of study selection 
 
Records identified through online 































Additional records identified 
through other sources (n = 0) 
Duplicates removed  
(n = 623) 
Records screened by title 
and abstract (n = 2540) 
Excluded based on title 
and abstract (n = 2480) 
Full-text articles assessed 
for eligibility  
(n = 60) 
Full-text articles excluded, 
with reasons (n = 45) 
 
 Insufficient statistical 
data (n = 2) 
 Study design (n = 10) 
 Mixture supplement (n = 
13) 
 Not suitable controls (n 
= 20) 
Finally,  
15 full-text articles 



































Figure 2, B 
 
 
Figure 3. Findings from subgroup analysis based on age (< 56, > 56 years old) (A), baseline blood 
pressure (< 130, > 130 mmHg) (B), duration (< 16, > 16 weeks) (C) and region (Asia, Europe, 













































































Figure 3, D 
 
 
Figure 4. Findings from subgroup analysis based on age (< 56, > 56 years old) (A), baseline blood 
pressure (< 130, > 130 mmHg) (B), duration (< 16, > 16 weeks) (C) and region (Asia, Europe, 
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Figure 5, D 
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Table 1. Characteristics of the included RCTs 
Study Country Type of study Population 
Age group 
(C vs. I) 
Body weight  
(C vs. I) 
BMI 
































and / or hypertensive 
52.2 vs. 
52.2 
83.8 vs. 85.1 
27.2 vs. 
27.6 
Soy protein 50 5 142 87.1 












276 12 134.7 84.7 






61.1 vs. 64.1 
23.8 vs. 
24.4 




















Hypercholesterolemic 58 vs. 60.6 75.3 vs. 77.1 
25.6 vs. 
26.4 























































































































180 25 125.9 78.2 































































































57.6 vs. 56.5 NR 
Soy 
isoflavone 
180 24 131.9 81.6 













Table 2. The methodological quality of included RCTs on effect of soy intake on blood pressure based on review authors’ judgments 















Teede (2001)        
Sagara (2004)        
He (2005)        
Kim (2005)        
Hermansen (2005)        
Aubertin-Leheudre (2008)        
Chan (2008)        
Kwak (2010)        











Liu (2013)        
Kim (2013)        
Squadrito (2013)        
Cheng (2013)        
Husain (2015)        











 Table 3. Meta-regression analysis by age, duration and baseline blood pressure for SBP 
and SBP. 
Confounders Coefficient 95 % CI P-value 
SBP 
Age 0.38 -0.03, 0.80 0.07 
Duration 0.11 -0.05, 0.28 0.17 
Baseline SBP -0.004 -0.31, 0.30 0.97 
DBP 
Age 0.20 -0.04, 0.45 0.10 
Duration 0.04 -0.06, 0.16 0.94 
Baseline DBP -0.16 -0.53, 0.19 0.33 
CI (confidence intervals); SBP (systolic blood pressure); DBP (diastolic blood pressure) 
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